Novel CAR T-Cell Therapy Achieves 100% MRD Negativity in Patients With Newly-Diagnosed Myeloma
BCMA/CD19 dual-targeting FasTCAR-T cells showed a high objective response rate in a study of patients with newly diagnosed high-risk multiple myeloma.
PROs Data Support Use of Upfront Daratumumab Quadruplet for Transplant Eligible, Newly-Diagnosed MM
Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.
Mezigdomide With Dexamethasone Appears Active in Heavily Pretreated Patients With Multiple Myeloma
In the CC-92480-MM-001, mezigdomide With dexamethasone demonstrated positive safety and efficacy in patients with heavily-pretreated multiple myeloma.
Elranatamab Induces Promising Responses in Patients With Penta/Triple-Refractory Myeloma
Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.
Teclistamab, Daratumumab, and Lenalidomide Demonstrates Encouraging Safety in RRMM
Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
Talquetamab Elicits Higher Treatment Responses in Heavily Pre-treated R/R Multiple Myeloma
The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512